RxDoctor Payments Data

Taylor Klein

Nurse Practitioner · Billings, MTNPI 1508594078

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $240 and has fallen 83.6% since, to $39 in 2025.

$524in general payments, 2019–2025

Across 25 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$94
  • Takeda Pharmaceuticals U.S.A., Inc.$84
  • Pfizer$66
  • Regeneron Healthcare Solutions, Inc.$47
  • Ipsen Biopharmaceuticals, Inc$43
  • Sandoz$35
  • plus $156 from 7 others

What the payments were for

  • Food & beverage$49494%
  • Education$306%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$524 in reported general payments places this provider in the 85th percentile of 357 nurse practitioner providers in Montana.

See all nurse practitioner providers in Montana

Medicare billing

Part B allowed, 2024
$49,949
Medicare patients
365
Services billed
452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$351,623
XifaxanRifaximin15$36,976
Budesonide DrBudesonide12$1,180
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl55$946
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl34$537
Pantoprazole Sodium58$489
Ondansetron OdtOndansetron12$265
Dicyclomine Hcl16$248
Omeprazole18$197
Amitriptyline Hcl16$79
Lactulose12$68
Spironolactone11$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$17$351,62313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 357 nurse practitioner providers in Montana.

Other nurse practitioner in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →